Clinical Cancer Drugs,volume 3,issue 2  (10-2016)

Period of time： 2016年2期

Publisher： Bentham Science Publishers

Founded in： 2014

Total resources： 8

E-ISSN： 2212-6988|3|2

ISSN： 2212-697x

Subject： R9 Pharmacy

Favorite

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Clinical Cancer Drugs,volume 3,issue 2

Menu

Meet Our Editor-in-Chief

Clinical Cancer Drugs,volume 3,issue 2 , Vol. 3, Iss. 2, 2016-10 , pp. 75-75

Bentham Science Publishers

Abstract Access to resources Recommend Favorite

Novel Antibody Therapeutics Targeting Mesothelin In Solid Tumors

Clinical Cancer Drugs,volume 3,issue 2 , Vol. 3, Iss. 2, 2016-10 , pp. 76-86

Bentham Science Publishers

Abstract Access to resources Recommend Favorite

Efficacy of Therapy with c-Met/HGF Inhibitors in Solid Tumors: A Systematic Review Based on 24 Clinical Trials

Clinical Cancer Drugs,volume 3,issue 2 , Vol. 3, Iss. 2, 2016-10 , pp. 87-99

Bentham Science Publishers

Abstract Access to resources Recommend Favorite

Efficacy of Bacteria in Cancer Immunotherapy: Special Emphasis on the Potential of Mycobacterial Species

Clinical Cancer Drugs,volume 3,issue 2 , Vol. 3, Iss. 2, 2016-10 , pp. 100-108

Bentham Science Publishers

Abstract Access to resources Recommend Favorite

Ameliorated Chemotherapeutic Potential of Diverse Dose Flouropyrimidine Therapy By Etodolac via NF-?B Pathway, PPAR-? Expression and COX-II Inhibition in DMH Induced Colon Cancer Rats

Clinical Cancer Drugs,volume 3,issue 2 , Vol. 3, Iss. 2, 2016-10 , pp. 109-120

Bentham Science Publishers

Abstract Access to resources Recommend Favorite

Evaluation of Antitumor Potential of Forskolin and Andrographolide Employing Potato Tumor Bioassay Model

Clinical Cancer Drugs,volume 3,issue 2 , Vol. 3, Iss. 2, 2016-10 , pp. 121-130

Bentham Science Publishers

Abstract Access to resources Recommend Favorite

Transforming Mutations of Jak3 (A573V and M511I) Show Differential Sensitivity to Selective Jak3 Inhibitors

Clinical Cancer Drugs,volume 3,issue 2 , Vol. 3, Iss. 2, 2016-10 , pp. 131-137

Bentham Science Publishers

Abstract Access to resources Recommend Favorite

Tumor-selective Cytotoxicity of a Novel Pentadiene Analogue on Human Leukemia/lymphoma Cells

Clinical Cancer Drugs,volume 3,issue 2 , Vol. 3, Iss. 2, 2016-10 , pp. 138-146

Bentham Science Publishers

Abstract Access to resources Recommend Favorite

ACKNOWLEDGEMENTS TO REVIEWERS

Clinical Cancer Drugs,volume 3,issue 2 , Vol. 3, Iss. 2, 2016-10 , pp. 147-147

Bentham Science Publishers

Abstract Access to resources Recommend Favorite

Total 9 item(s)